AVX 13616

• Description:

  AVX 13616 shows the potent in vivo antibacterial activity of Avexa’s lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens. IC50 value: 2-4 ug/ml (MICs) Target: antibacterial agent AVX13616 was as active as mupirocin in a nasal decolonization model but required only a single application. The compounds are being developed for topical indications and/or wound infection/catheter-related infections. AVX13616 and other compounds showed broad spectrum antibacterial activity against a range of isolates with MICs of 2-4 micrograms per millilitre against S. aureus, coagulase negative staphylococci, enterococci, MRSA, VISA and VRSA. A single application of 5% (w/w) AVX13616 (approximately equimolar to 2% mupirocin) was as effective as 2% mupirocin administered twice a day for five days in nasal decolonisation of MRSA in mice.

• UNSPSC:

  12352005

• Target:

  Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/avx-13616.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C (N[C@H] (CCCCN) C (N[C@H] (CCCNC (N) =N) C (N[C@@H] (CC (C) C) C (OCCC (C) C) =O) =O) =O) COC1=[C@@] ([C@@]2=C (OCCC (C) C) C=CC3=C2C=CC=C3) C (C=CC=C4) =C4C=C1.Cl.Cl

• Molecular Formula:

  C50H73Cl2N7O7

• Molecular Weight:

  955.06

• References & Citations:

  [1]Avexa Presents Data from Apricitabine and Antibacterial Programs at two International Conferences

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  900814-48-4